Holen Sie sich die Stockscreener-App
0.1108
3.45%
0.0037
Handel nachbörslich:
.12
0.0092
+8.30%
Schlusskurs vom Vortag:
$0.1071
Offen:
$0.1045
24-Stunden-Volumen:
3.33M
Relative Volume:
0.24
Marktkapitalisierung:
$4.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.61M
KGV:
-0.011
EPS:
-10.05
Netto-Cashflow:
$-13.91M
1W Leistung:
-19.54%
1M Leistung:
-7.28%
6M Leistung:
-99.00%
1J Leistung:
-99.89%
1-Tages-Spanne:
$0.1045
$0.1158
1-Wochen-Bereich:
$0.10
$0.1381
52-Wochen-Spanne:
$0.0955
$137.50
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Firmenname
Cns Pharmaceuticals Inc
Sektor
Branche
Telefon
1-800-946-9185
Adresse
2100 WEST LOOP SOUTH, HOUSTON
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Eingeleitet | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com UK
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - AccessWire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire
CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex
Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
It is Poised to be a Bull Market for Cns Pharmaceuticals Inc (CNSP) - SETE News
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - BioSpace
Ladenburg Thalmann gives a Neutral recommendation for Cns Pharmaceuticals Inc (CNSP) - Knox Daily
Cns Pharmaceuticals Inc (CNSP) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan
A stock that deserves closer examination: Cns Pharmaceuticals Inc (CNSP) - US Post News
Ratio Examination: Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Wall Street analysts’ outlook for Cns Pharmaceuticals Inc (CNSP) - SETE News
Cns Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Titan Medical Inc (TMD-T) QuotePress Release - The Globe and Mail
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 - The Manila Times
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Cns Pharmaceuticals Inc (CNSP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Examining Cns Pharmaceuticals Inc (CNSP) stock is warranted - US Post News
CNS Therapeutics Market 2024 Share, Growth Forecast and Industry Outlook 2032 | Eli Lilly and Co. - 대구포스트
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
A new trading data show Cns Pharmaceuticals Inc (CNSP) is showing positive returns. - SETE News
Do investors need to be concerned about Cns Pharmaceuticals Inc (CNSP)? - US Post News
CNS (Central Nervous System) Therapeutics Market 2024 Size, Status and Global Outlook 2031 - Newstrail
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - AccessWire
Ratio Review: Analyzing Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Cns Pharmaceuticals Inc (CNSP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Brain cancer drugmaker CNS Pharma warns of possible Nasdaq delisting - Kursiv Media
An analyst sees good growth prospects for Cns Pharmaceuticals Inc (CNSP) - SETE News
What was Cns Pharmaceuticals Inc (CNSP)’s performance in the last session? - US Post News
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.15, Down by -0.54 - The Dwinnex
CNS Pharmaceuticals regains NASDAQ compliance - Investing.com
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement - AccessWire
Such Is The Power Of Cns Pharmaceuticals Inc (NASDAQ: CNSP) - Stocks Register
CNS Pharmaceuticals (NASDAQ:CNSP) Upgraded to “Buy” at Maxim Group - Defense World
CNSP Stock: Exploring Cns Pharmaceuticals Inc’s Growth - The InvestChronicle
Maxim raises CNS Pharmaceuticals to buy, cites improved financial position - Investing.com
Finanzdaten der Cns Pharmaceuticals Inc-Aktie (CNSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cns Pharmaceuticals Inc-Aktie (CNSP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Evans Carl Anthony | Director |
Feb 01 '24 |
Buy |
0.30 |
33,333 |
10,000 |
33,458 |
| Downs Christopher | Chief Financial Officer |
Feb 01 '24 |
Buy |
0.30 |
66,666 |
20,000 |
103,438 |
| Climaco John M | Chief Executive Officer |
Feb 01 '24 |
Buy |
0.30 |
166,666 |
50,000 |
215,676 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):